Edward Blackall Fuchs

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom.

GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.

SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark.

Oxitec Ltd. develops solutions for controlling harmful insect pests. It provides biological and development research services in controlling insects that spread diseases and damage crops. Its products include Diamond back moth, Pink bollworm, Medfl,y Mexfly, and Olive fly. The company was founded by Luke Alphey on August 15, 2002 and is headquartered in Abingdon, the United Kingdom.

Oxford University Innovation Ltd (Oxford University Innovation) is a venture capital subsidiary of University of Oxford founded in 1987 and spun out in 2010. The firm is headquartered in London, United Kingdom.

Sapphire Energy Ltd. is a British company that generates and supplies energy. The company is based in Belfast, UK. The company was founded in 2013.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Biome Oxford Ltd. engages in the development of a non-invasive and cost-effective device to address a growing demand for microbiome studies. The company was founded by Soren Thomsen and Matthias Thurner in 2014 is headquartered in Marston, the United Kingdom.